| Methods |
Randomised |
| Participants |
402 patients with stage II‐IIIB |
| Interventions |
Chemotherapy with vinblastine and cisplatin plus daily RT to 60Gy commencing day 1 (concurrent) or day 50 (sequential) |
| Outcomes |
1‐year survival 63% v 57%; 2‐year survival 37% v 31% |
| Notes |
Third arm of study included hyperfractionated RT (total number of patients in study = 610). This study was published as an abstract. |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Adequate sequence generation? |
Unclear risk |
Not reported. |
| Allocation concealment? |
Unclear risk |
Not reported. |
| Incomplete outcome data addressed?
All outcomes |
Unclear risk |
Numbers are presented, although causes of patients loss and groups they belong to aren't. "610 enrolled patients, 595 analyzable patients". |
